HLA-B27 misfolding: a solution to the spondyloarthropathy conundrum?

Compelling evidence indicates that HLA-B27 is directly involved in the etiopathogenesis of the spondyloarthropathies (SpAs). Several hypotheses based on its native antigenic structure, the peptides it presents and mimicry with bacterial epitopes, have been proposed. However, these potential mechanisms remain largely unsupported by human studies and transgenic animal models. Recent work demonstrating that HLA-B27 misfolds offers a novel alternative hypothesis. Here, we review this new information on the folding and assembly of HLA-B27, and discuss consequences of misfolding that could be relevant to the pathogenesis of SpAs.

[1]  R. Hammer,et al.  Inflammatory disease in HLA‐B27 transgenic rats , 1999, Immunological reviews.

[2]  T. Rapoport,et al.  Sec6l-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction , 1996, Nature.

[3]  J. Ringrose.  HLA-B27 associated spondyloarthropathy, an autoimmune disease based on crossreactivity between bacteria and HLA-B27? , 1999, Annals of the rheumatic diseases.

[4]  J. Heesemann,et al.  HLA-B27 as a relative risk factor in ankylosing enthesopathy in transgenic mice. , 1995, Human immunology.

[5]  J. Shabanowitz,et al.  Susceptibility to ankylosing spondylitis correlates with the C‐terminal residue of peptides presented by various HLA‐B27 subtypes , 1997, European journal of immunology.

[6]  P. Wordsworth.  Genes in the spondyloarthropathies. , 1998, Rheumatic diseases clinics of North America.

[7]  L. Pelliniemi,et al.  HLA‐B27 modulates intracellular survival of Salmonella enteritidis in human monocytic cells , 1997, European journal of immunology.

[8]  C. López-Larrea,et al.  Immunogenetics, HLA-B27 and spondyloarthropathies. , 1999, Current opinion in rheumatology.

[9]  M. Kitamura,et al.  NF‐κB‐mediated self defense of macrophages faced with bacteria , 1999 .

[10]  H. Luthra,et al.  Spontaneous inflammatory arthritis in HLA-B27 transgenic mice lacking beta 2-microglobulin: a model of human spondyloarthropathies , 1995, The Journal of experimental medicine.

[11]  H. Luthra,et al.  Animal models of human leukocyte antigen B27-linked arthritides. , 1998, Rheumatic diseases clinics of North America.

[12]  P. Baeuerle,et al.  Function and activation of NF-kappa B in the immune system. , 1994, Annual review of immunology.

[13]  E. Coto,et al.  HLA-B27 polymorphism and worldwide susceptibility to ankylosing spondylitis. , 1997, Tissue antigens.

[14]  K. Tokunaga,et al.  Association of HLA-B39 with HLA-B27-negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients. Evidence for a role of the peptide-anchoring B pocket. , 1995, Arthritis and rheumatism.

[15]  R. Hammer,et al.  The Specificity of Peptides Bound to Human Histocompatibility Leukocyte Antigen (HLA)-B27 Influences the Prevalence of Arthritis in HLA-B27 Transgenic Rats , 1998, The Journal of experimental medicine.

[16]  P I Terasaki,et al.  High association of an HL-A antigen, W27, with ankylosing spondylitis. , 1973, The New England journal of medicine.

[17]  K. Lewis,et al.  In vivo dimeric association of class I MHC heavy chains. Possible relationship to class I MHC heavy chain-beta 2-microglobulin dissociation. , 1993, Journal of immunology.

[18]  H. Rammensee,et al.  Peptides naturally presented by MHC class I molecules. , 1993, Annual review of immunology.

[19]  A. Toubert,et al.  Differences in endogenous peptides presented by HLA-B*2705 and B*2703 allelic variants. Implications for susceptibility to spondylarthropathies. , 1996, The Journal of clinical investigation.

[20]  A. McMichael,et al.  Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure. , 1999, Journal of immunology.

[21]  J. Archer,et al.  Chemical reactivity of an HLA‐B27 thiol group , 1993, European journal of immunology.

[22]  S. Rowland-Jones,et al.  Allele-specific B pocket transplant in class I major histocompatibility complex protein changes requirement for anchor residue at P2 of peptide. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S. Rowland-Jones,et al.  Differences in peptide presentation between B27 subtypes: the importance of the P1 side chain in maintaining high affinity peptide binding to B*2703. , 1994, Immunity.

[24]  H. Luthra,et al.  HLA-B27 heavy chains contribute to spontaneous inflammatory disease in B27/human beta2-microglobulin (beta2m) double transgenic mice with disrupted mouse beta2m. , 1996, The Journal of clinical investigation.

[25]  H. Luthra,et al.  Spontaneous inflammatory disease in HLA-B27 transgenic mice is independent of MHC class II molecules: a direct role for B27 heavy chains and not B27-derived peptides. , 1998, Journal of immunology.

[26]  A. McNeil,et al.  Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. , 1996, QJM : monthly journal of the Association of Physicians.

[27]  H. Rammensee,et al.  Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. , 1999, Journal of immunology.

[28]  C. López-Larrea,et al.  The role of HLA-B27 polymorphism and molecular mimicry in spondylarthropathy. , 1998, Molecular medicine today.

[29]  R D Sturrock,et al.  Ankylosing spondylitis and HL-A 27. , 1973, Lancet.

[30]  F. Roncal,et al.  Modulation at multiple anchor positions of the peptide specificity of HLA-B27 subtypes differentially associated with ankylosing spondylitis. , 1999, Arthritis and rheumatism.

[31]  R. Tampé,et al.  A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. , 1997, Science.

[32]  H. Whittle,et al.  Ankylosing spondylitis in West Africans—evidence for a non-HLA-B27 protective effect , 1997, Annals of the rheumatic diseases.

[33]  P. Cresswell,et al.  Mechanisms of MHC class I--restricted antigen processing. , 1998, Annual review of immunology.

[34]  P. Cresswell,et al.  Misfolded major histocompatibility complex class I heavy chains are translocated into the cytoplasm and degraded by the proteasome. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  W. Tsai,et al.  Expression of arthritis-causing HLA-B27 on Hela cells promotes induction of c-fos in response to in vitro invasion by Salmonella typhimurium. , 1998, The Journal of clinical investigation.

[36]  William E. Balch,et al.  Integration of endoplasmic reticulum signaling in health and disease , 1999, Nature Medicine.

[37]  M. Khan,et al.  HLA-B27 polymorphism and association with disease. , 2000, The Journal of rheumatology.

[38]  P. Parham.  Presentation of HLA Class I‐Derived Peptides: Potential Involvement in Allorecognition and HLA‐B27‐Associated Arthritis , 1996, Immunological reviews.

[39]  L. Hannick,et al.  HLA class I polymorphism: structure and function and still questions. , 1997, Human immunology.

[40]  J. Frelinger,et al.  A point mutation in HLA-A*0201 results in failure to bind the TAP complex and to present virus-derived peptides to CTL. , 1996, Immunity.

[41]  H. Rammensee,et al.  Naturally occurring A pocket polymorphism in HLA-B*2703 increases the dependence on an accessory anchor residue at P1 for optimal binding of nonamer peptides. , 1997, Journal of immunology.

[42]  A. Rickinson,et al.  HLA-B27 subtype polymorphism and CTL epitope choice: studies with EBV peptides link immunogenicity with stability of the B27:peptide complex. , 1998, Journal of immunology.

[43]  H. Pahl.  Signal transduction from the endoplasmic reticulum to the cell nucleus. , 1999, Physiological reviews.